Skip to main content

Charles River Laboratories stock price and financials

  • CRL · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$337.97−0.83%Close 13 Nov 2026
Market value
$16.06B
P/E
399.57
EV / EBITDA
42.52
Beta · 1 year
1.27
Return · 1 year
+97.1%
52-week range$146.20 — $379.63

Share price close 16 Nov 2026

+9.4%1 monthHigh $376.10Low $300.02
$300$320$340$360$380Q3 FY2026 report filed 4 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+122%6 monthsHigh $376.10Low $149.93
$100$200$300$400Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+68.0%year to dateHigh $376.10Low $149.93
$100$200$300$400Q4 FY2025 report filed 18 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+99.7%1 yearHigh $376.10Low $149.93
$100$200$300$400Q4 FY2025 report filed 18 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+78.7%3 yearsHigh $376.10Low $99.75
$0$100$200$300$400Q4 FY2023 report filed 14 Feb 2024Q1 FY2024 report filed 9 May 2024Q2 FY2024 report filed 7 Aug 2024Q3 FY2024 report filed 6 Nov 2024Q4 FY2024 report filed 19 Feb 2025Q1 FY2025 report filed 7 May 2025Q2 FY2025 report filed 6 Aug 2025Q3 FY2025 report filed 5 Nov 2025Q4 FY2025 report filed 18 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+356%10 yearsHigh $458.30Low $71.87
$0$100$200$300$400$500Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Charles River Laboratories reported revenue of $4.02 billion for fiscal year 2025 (the twelve months to 27 Dec 2025), down 0.9% from fiscal 2024. Net income was −$144 million and diluted earnings per share −$2.91.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 26 Sep 2026), revenue was $983 million, down 2.2% from a year earlier.

Figures from Charles River Laboratories's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 4 Nov 2026.

Against Health Care

Growth
Lower half
Revenue +6.5% a year over five years · 22nd of 37
Profitability
Bottom quarter
Return on invested capital 5.5%, five-year average · 32nd of 38
Balance sheet
Bottom quarter
Net debt 6.0× EBITDA · 36th of 38
Valuation
Dearer than most
P/E 399.6 · 36th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$4.02B−0.9%
Net income
−$144.3M−750%
Diluted EPS
−$2.91−1555%
Gross margin
33.0%+0.1 pts
Free cash flow
$518.5M+3.4%
Net debt
$2.41B−6.6%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$1B$0$1B$2B$3B$4B$5BRevenue, FY16: $1.68BNet income, FY16: $154.76MFY16Revenue, FY17: $1.86BNet income, FY17: $123.36MFY17Revenue, FY18: $2.27BNet income, FY18: $226.37MFY18Revenue, FY19: $2.62BNet income, FY19: $252.02MFY19Revenue, FY20: $2.92BNet income, FY20: $364.3MFY20Revenue, FY21: $3.54BNet income, FY21: $390.98MFY21Revenue, FY22: $3.98BNet income, FY22: $486.23MFY22Revenue, FY23: $4.13BNet income, FY23: $474.62MFY23Revenue, FY24: $4.05BNet income, FY24: $22.2MFY24Revenue, FY25: $4.02BNet income, FY25: −$144.34MFY25

Latest quarter · Q3 FY2026 to 26 Sep 2026, filed 4 Nov 2026 · Full results →

Revenue
$982.7M−2.2% on a year
Gross margin
36.4%+2.7 pts on a year
Operating income
$202.6M+51.4% on a year
Net income
$333.1M+512% on a year
Diluted EPS
$6.86+524% on a year
Free cash flow
$207.3M+16.3% on a year

Comparable companies All of Health Care →

Charles River Laboratories beside the other S&P 500 members in Life Sciences Tools & Services, by market value.

Charles River Laboratories and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Charles River LaboratoriesCRL$16.06B−0.8%+97.1%−1.2%1.0%399.6
Danaher CorporationDHR$163.0B+0.4%+6.2%+5.5%16.9%37.6
Agilent TechnologiesA$48.72B+0.5%+14.8%+8.6%19.5%33.8
IQVIAIQV$43.52B−2.2%+20.0%+8.8%8.1%31.2
IlluminaILMN$30.43B−4.2%+65.3%+5.8%19.7%34.0
Bio-TechneTECH—−0.1%+18.6%———
Mettler ToledoMTD—+0.5%+20.1%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-50%0%50%100%33.0%0.6%-3.6%FY16FY19FY22FY25

Charles River Laboratories revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Charles River Laboratories revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
DSA$2.11B$2.45B+16.1%$2.62B+6.9%$2.45B−6.3%$2.40B−2.0%
RMS$690.4M$739.2M+7.1%$792.3M+7.2%$829.4M+4.7%$846.1M+2.0%
Manufacturing$742.5M$789.6M+6.3%$721.4M−8.6%$769.3M+6.6%$766.4M−0.4%
Total revenue$3.54B$3.98B$4.13B$4.05B$4.02B

By product

Charles River Laboratories revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Cost of services provided (excluding amortization of intangible assets)$2.76B$3.22B+16.7%$3.44B+6.9%$3.30B−4.0%$3.25B−1.6%
Cost of products sold (excluding amortization of intangible assets)$784.6M$759.2M−3.2%$689.4M−9.2%$745.9M+8.2%$765.3M+2.6%
Total revenue$3.54B$3.98B$4.13B$4.05B$4.02B

By region

Charles River Laboratories revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$1.93B$2.34B+21.1%$2.35B+0.2%$2.24B−4.6%$2.14B−4.4%
Europe$1.04B$1.03B−0.4%$1.08B+4.3%$1.08B+0.1%$1.10B+2.3%
Canada$339.1M$399.0M+17.7%$487.3M+22.1%$482.1M−1.1%$501.0M+3.9%
Asia Pacific$222.9M$192.8M−13.5%$200.8M+4.1%$197.0M−1.9%$205.0M+4.1%
Other$7.29M$9.96M+36.6%$16.85M+69.2%$52.82M$64.86M+22.8%
Total revenue$3.54B$3.98B$4.13B$4.05B$4.02B

Financial statements

Fiscal years, the latest ending 27 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Charles River Laboratories income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$1.68B$1.86B$2.27B$2.62B$2.92B$3.54B$3.98B$4.13B$4.05B$4.02B
Revenue growth+23.3%+10.5%+22.0%+15.7%+11.5%+21.1%+12.3%+3.9%−1.9%−0.9%
Gross profit$1.40B$1.57B—$958.3M$1.07B$1.33B$1.46B$1.50B$1.33B$1.32B
Operating income$237.6M$288.3M$331.4M$351.2M$432.7M$589.9M$651.0M$617.3M$227.3M$25.16M
Net income$154.8M$123.4M$226.4M$252.0M$364.3M$391.0M$486.2M$474.6M$22.20M−$144.3M
Diluted EPS$3.23$2.54$4.62$5.07$7.20$7.60$9.48$9.22$0.20−$2.91
Gross margin83.5%84.4%—36.6%36.7%37.7%36.8%36.4%32.9%33.0%
Operating margin14.1%15.5%14.6%13.4%14.8%16.7%16.4%14.9%5.6%0.6%
Net margin9.2%6.6%10.0%9.6%12.5%11.0%12.2%11.5%0.5%−3.6%

Cash flow

Charles River Laboratories cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$316.9M$318.1M$441.1M$480.9M$546.6M$760.8M$619.6M$683.9M$734.6M$737.6M
Capital expenditure$55.29M$82.43M$140.1M$140.5M$166.6M$228.8M$324.7M$318.5M$233.0M$219.2M
Free cash flow$261.6M$235.6M$301.1M$340.4M$380.0M$532.0M$294.9M$365.4M$501.6M$518.5M

Balance sheet and shares

Charles River Laboratories balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$117.6M$163.8M$195.4M$238.0M$228.4M$241.2M$233.9M$276.8M$194.6M$213.8M
Total debt$1.21B$1.12B$1.65B$2.02B$2.16B$2.95B$3.15B$3.12B$2.78B$2.63B
Shareholders' equity$836.8M$1.05B$1.32B$1.63B$2.11B$2.53B$2.98B$3.60B$3.46B$3.16B
Diluted shares48.0M48.6M49.0M49.7M50.6M51.4M51.3M51.5M51.6M49.6M

Quarterly figures

The last eight fiscal quarters, the latest ending 26 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Charles River Laboratories quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.00B$984.2M$1.03B$1.00B$994.2M$995.8M$1.00B$982.7M
Revenue, year on year−1.1%−2.7%+0.6%−0.5%−0.8%+1.2%−2.7%−2.2%
Gross margin28.4%32.3%34.6%33.7%31.1%29.6%36.2%36.4%
Operating income−$167.7M$74.67M$100.1M$133.8M−$283.4M$119.9M$119.9M$202.6M
Net income−$214.5M$25.47M$52.33M$54.42M−$276.6M−$14.84M−$1.48M$333.1M
Diluted EPS−$4.20$0.50$1.06$1.10−$5.62−$0.30−$0.03$6.86
Free cash flow$83.75M$112.4M$169.3M$178.2M$58.57M−$14.83M$148.6M$207.3M

Operating KPIs

The operating figures Charles River Laboratories reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Charles River Laboratories operating KPIs
KPILatestPeriodChange on a yearRecent periods
Organic revenue (change on a year)5.9%quarter to 26 Sep 2026down 0.6 points
Revenue$995.8Mquarter to 28 Mar 2026up 1.2%
Remaining performance obligations$675.3Mat 26 Sep 2026up 4.0%
Cost of services provided (excluding amortization of intangible assets) revenue$780.3Mquarter to 26 Sep 2026down 3.4%
Cost of products sold (excluding amortization of intangible assets) revenue$202.4Mquarter to 26 Sep 2026up 2.8%
DSA revenue$596.3Mquarter to 26 Sep 2026down 0.7%
RMS revenue$207.5Mquarter to 26 Sep 2026down 2.8%
Manufacturing revenue$178.9Mquarter to 26 Sep 2026down 6.2%
United States revenue$541.7Mquarter to 26 Sep 2026up 0.8%
Europe revenue$240.1Mquarter to 26 Sep 2026down 13.5%
Canada revenue$120.6Mquarter to 26 Sep 2026up 3.2%
Asia Pacific revenue$61.6Mquarter to 26 Sep 2026up 19.3%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Charles River Laboratories's revenue in fiscal 2025?

$4.02 billion for fiscal year 2025 (the twelve months to 27 Dec 2025), as reported in its annual report.

What was Charles River Laboratories's net income in fiscal 2025?

−$144 million for fiscal year 2025 (the twelve months to 27 Dec 2025).

What were Charles River Laboratories's diluted earnings per share in fiscal 2025?

−$2.91 for fiscal year 2025 (the twelve months to 27 Dec 2025).

What is Charles River Laboratories's gross margin?

33.0% for fiscal year 2025 (the twelve months to 27 Dec 2025): gross profit divided by revenue.

What is Charles River Laboratories's operating margin?

0.6% for fiscal year 2025 (the twelve months to 27 Dec 2025): operating income divided by revenue.

How much free cash flow did Charles River Laboratories generate in fiscal 2025?

$518 million for fiscal year 2025 (the twelve months to 27 Dec 2025): operating cash flow less capital expenditure.

Where does Charles River Laboratories's revenue come from?

In fiscal 2025, by segment: DSA $2.40B (60%), RMS $846.1M (21%), Manufacturing $766.4M (19%), out of $4.02B in all, as stated in its annual report.

In the terminal

Twenty years of Charles River Laboratories's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans